2015-02-19 20:18:02 UTC

Infection Risks Continue with Duodenoscopes Used for ERCP

Feb. 19, 2015

Patient infections after ERCP continue to be reported, which are unacceptable. AGA leadership has been working with FDA and endoscopy manufacturers to help monitor and solve this critical patient safety concern.

AGA and gastroenterologists will not tolerate any procedure-related infections, which continue to occur. Any cases of patient infection tied to duodenoscopes are not acceptable and need to be thoroughly investigated with solutions developed.

AGA leadership has worked with FDA to develop a safety communication, which was released today, “Design of Endoscopic Retrograde Cholangiopancreatography (ERCP) Duodenoscopes May Impede Effective Cleaning.” 

Through the AGA Center for GI Innovation and Technology, we are uniquely positioned to work with the FDA device branch and endoscope manufacturers. We have offered our help to resolve and monitor this issue. Our goal is safe patient care with no preventable infections. 

Read More.

More on Colorectal Cancer

Principles of GI for the NP and PA

Aug. 10, 2018

Hear from the experts as they provide you with critical updates on treating and managing patients with a variety of GI disorders.

2018 AGA Postgraduate Course

June 2, 2018

Secure your spot for this clinically focused, multi-topic course that offers immediately applicable information. Held in conjunction with DDW®. Save $75 when you register by April 18.

Advocate CMS, close the colonoscopy loophole

March 8, 2018

AGA urges CMS to address the cost sharing problem that arises when screening colonoscopies become diagnostic for Medicare patients.